Characterization of the NPC1L1 gene and proteome from an exceptional responder to ezetimibe

Atherosclerosis

Volumn 246, Issue , 2016, Pages 78-86

  Schweitzer, Morris ^a,b   Makhoul, Sandra ^b   Paliouras, Miltiadis ^b,c   Beitel, Lenore K ^a,b   Gottlieb, Bruce ^b   Trifiro, Mark ^a,c   Chowdhury, Shafinaz F ^d   Zaman, Naif M ^d   Wang, Edwin ^d   Davis, Harry ^e   Chalifour, Lorraine E ^a,b,c  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^e CVPATH INSTITUTE   (United States)

Author keywords

Cholesterol; Cholesterol absorption; Cholesterol cell and tissue; Drug therapy hypolipidemic drugs; Genetics; Proteomics

Indexed keywords

AMINO ACID; EZETIMIBE; FLOTILLIN 1; FLOTILLIN 2; GENOMIC DNA; PROTEOME; BIOLOGICAL MARKER; GENETIC MARKER; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEMBRANE PROTEIN; NPC1L1 PROTEIN, HUMAN; PROTEIN BINDING;

ARTICLE; BINDING AFFINITY; CELL MEMBRANE; CELL PROLIFERATION; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; FAMILIAL HYPERCHOLESTEROLEMIA; GENE; GENE LOCATION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOLOCALIZATION; NIEMANN PICK C 1 LIKE 1 GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; TREATMENT RESPONSE; WILD TYPE; ANTAGONISTS AND INHIBITORS; BLOOD; CHEMISTRY; DNA MUTATIONAL ANALYSIS; DOWN REGULATION; FEMALE; GENETIC MARKER; GENETIC TRANSFECTION; GENETICS; GENOTYPE; HEK293 CELL LINE; HYPERLIPOPROTEINEMIA TYPE II; MALE; METABOLISM; MOLECULAR DYNAMICS; MOLECULAR MODEL; MUTATION; PHENOTYPE; PROCEDURES; PROTEIN CONFORMATION; TREATMENT OUTCOME;

ANTICHOLESTEREMIC AGENTS; BIOMARKERS; CHOLESTEROL, LDL; DNA MUTATIONAL ANALYSIS; DOWN-REGULATION; EZETIMIBE; FEMALE; GENETIC MARKERS; GENOTYPE; HEK293 CELLS; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MEMBRANE PROTEINS; MODELS, MOLECULAR; MOLECULAR DYNAMICS SIMULATION; MUTATION; PHENOTYPE; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEOMICS; TRANSFECTION; TREATMENT OUTCOME;

EID: 84952642087     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.12.032     Document Type: Article

References (47)

1. Cholesterol Treatment Trialists, C Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010, 376:1670-1681.
2. Dietschy J.M., Turley S.D., Spady D.K. Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. J. Lipid Res. 1993, 34:1637-1659.
3. Davis H.R., Veltri E.P. Zetia: inhibition of Niemann-Pick C1 like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treat hyperlipidemia. J. Atheroscler. Thromb. 2007, 14:99-108.
4. Knopp R.H., Gitter H., Truitt T., Bays H., Manion C.V., Lipka L.J., LeBeaut A.P., Suresh R., Yang B., Veltri E.P. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur. Heart J. 2003, 24:729-741.
5. Pisciotta L., Fasano T., Bellocchio A., Bocchi L., Sallo R., Fresa R., Colangeli I., Cantafora A., Calandra S., Bertolini S. Effect of ezetimibe coadministered with statins in genotype-confirmed heterozygous FH patients. Atherosclerosis 2007, 194:e116-e122.
6. Kruit J., Groen A., van Berkel T., Kuipers F. Emerging roles of the intestine in control of cholesterol metabolism. World J. Gastroenterol. 2006, 12:6429-6439.
7. Davies J.P., Levy B., Ioannou Y.A. Evidence for a Niemann-Pick C (NPC) gene family: identification and characterization of NPC1L1. Genomics 2000, 65:137-145.
8. Altmann S., Davis H., Zhu L., Yao X., Hoos L., Tetzloff G., Iyer S., Maguire M., Golovko A., Zeng M. Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption. Science 2004, 303:1201-1204.
9. Garcia-Calvo M., Lisnock J., Bull H., Hawes B., Burnett D., Braun M., Crona J., Davis H., Dean D., Detmers P. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc. Natl. Acad. Sci. U. S. A. 2005, 102:8132-8137.
10. Hawes B.E., O'Neill K.A., Yao X., Crona J.H., Davis H.R., Graziano M.P., Altmann S.W. In vivo responsiveness to ezetimibe correlates with Niemann-Pick C1 Like-1 (NPC1L1) binding affinity: comparison of multiple species NPC1L1 orthologs. Mol. Pharmacol. 2007, 71:19-29.
11. Chang X., Zhou Z.-S., Li N., Bian Y., Wang Y.-J., Wang L.-J., Li B.-L., Song B.-L. Ezetimibe blocks the internalization of NPC1L1 and cholesterol in mouse small intestine. J. Lipid Res. 2012, 53:2092-2101.
12. Weinglass A.B., Kohler M., Schulte U., Liu J., Nketiah E.O., Thomas A., Schmalhofer W., Williams B., Bildl W., McMasters D.R., Dai K., Beers L., McCann M.E., Kaczorowski G.J., Garcia M.L. Extracellular loop C of NPC1L1 is important for binding to ezetimibe. Proc. Natl. Acad. Sci. 2008, 105:11140-11145.
13. Chang D.K., Grimmond S.M., Evans T.J., Biankin A.V. Mining the genomes of exceptional responders. Nat. Rev. Cancer 2014, 14:291-292.
14. Martín B., Solanas-Barca M., García-Otín Á.L., Pampín S., Cofán M., Ros E., Rodríguez-Rey J.C., Pocoví M., Civeira F. An NPC1L1 gene promoter variant is associated with autosomal dominant hypercholesterolemia. Nutr. Metab. Cardiovasc. Dis. 2010, 20:236-242.
15. Fahmi S., Yang C., Esmail S., Hobbs H.H., Cohen J.C. Functional characterization of genetic variants in NPC1L1 supports the sequencing extremes strategy to identify complex trait genes. Hum. Mol. Genet. 2008, 17:2101-2107.
16. Hegele R.A., Guy J., Ban M.R., Wang J. NPC1L1 haplotype is associated with inter-individual variation in plasma low-density lipoprotein response to ezetimibe. Lipids Health Dis. 2005, 4:1-5.
17. Cohen J.C., Pertsemlidis A., Fahmi S., Esmail S., Vega G.L., Grundy S.M., Hobbs H.H. Multiple rare variants in NPC1L1 associated with reduced sterol absorption and plasma low-density lipoprotein levels. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:1810-1815.
18. Yamanashi Y., Takada T., Suzuki H. In-vitro characterization of the six clustered variants of NPC1L1 observed in cholesterol low absorbers. Pharmacogenet. Genomics 2009, 19:884-892.
19. Polisecki E., Peter I., Simon J.S., Hegele R.A., Robertson M., Ford I., Shepherd J., Packard C., Jukema J.W., de Craen A.J.M., Westendorp R.G.J., Buckley B.M., Schaefer E.J. Genetic variation at the NPC1L1 gene locus, plasma lipoproteins, and heart disease risk in the elderly. J. Lipid Res. 2010, 51:1201-1207.
20. Maeda T., Honda A., Ishikawa T., Kinoshita M., Mashimo Y., Takeoka Y., Yasuda D., Kusano J., Tsukamoto K., Matsuzaki Y., Teramoto T. A SNP of NPC1L1 affects cholesterol absorption in Japanese. J. Atheroscler. Thromb. 2010, 17:356-360.
21. Simon J.S., Karnoub M.C., Devlin D.J., Arreaza M.G., Qiu P., Monks S.A., Severino M.E., Deutsch P., Palmisano J., Sachs A.B., Bayne M.L., Plump A.S., Schadt E.E. Sequence variation in NPC1L1 and association with improved LDL-cholesterol lowering in response to ezetimibe treatment. Genomics 2005, 86:648-656.
22. Kwon H.J., Palnitkar M., Deisenhofer J. The structure of the NPC1L1 N-terminal domain in a closed conformation. PLoS One 2011, 6:e18722.
23. Kwon H.J., Abi-Mosleh L., Wang M.L., Deisenhofer J., Goldstein J.L., Brown M.S., Infante R.E. Structure of N-terminal domain of NPC1 reveals distinct subdomains for binding and transfer of cholesterol. Cell 2009, 137:1213-1224.
24. Jakalian A., Jack D.B., Bayly C.I. Fast, efficient generation of high-quality atomic charges. AM1-BCC model: II. Parameterization and validation. J. Comput. Chem. 2002, 23:1623-1641.
25. Hornak V., Abel R., Okur A., Strockbine B., Roitberg A., Simmerling C. Comparison of multiple Amber force fields and development of improved protein backbone parameters. Proteins Struct. Funct. Bioinforma. 2006, 65:712-725.
26. Case D.A., Cheatham T.E., Darden T., Gohlke H., Luo R., Merz K.M., Onufriev A., Simmerling C., Wang B., Woods R.J. The Amber biomolecular simulation programs. J. Comput. Chem. 2005, 26:1668-1688.
27. Jorgensen W.L., Chandrasekhar J., Madura J.D., Impey R.W., Klein M.L. Comparison of simple potential functions for simulating liquid water. J. Chem. Phys. 1983, 79:926.
28. Darden T., York D., Pedersen L. Particle mesh Ewald: an N.log (N) method for Ewald sums in large systems. J. Chem. Phys. 1993, 98:10089.
29. Ryckaert J.-P., Ciccotti G., Berendsen H.J. Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J. Comput. Phys. 1977, 23:327-341.
30. Naïm M., Bhat S., Rankin K.N., Dennis S., Chowdhury S.F., Siddiqi I., Drabik P., Sulea T., Bayly C.I., Jakalian A. Solvated interaction energy (SIE) for scoring protein-ligand binding affinities. 1. Exploring the parameter space. J. Chem. Inf. Model. 2007, 47:122-133.
31. Saba J., Bonneil E., Pomies C., Eng K., Thibault P. Enhanced sensitivity in proteomics experiments using FAIMS coupled with a hybrid linear ion trap/Orbitrap mass spectrometer. J. Proteome Res. 2009, 8:3355-3366.
32. Kearney P., Thibault P. Bioinformatics meets proteomics-bridging the gap between mass spectrometry data analysis and cell biology. J. Bioinform. Comput. Biol. 2003, 1:183-200.
33. Simard L.R., Viel J., Lambert M., Paradis G., Levy E., Delvin E.E., Mitchell G.A. The δ>15 Kb deletion French Canadian founder mutation in familial hypercholesterolemia: rapid polymerase chain reaction-based diagnostic assay and prevalence in Quebec. Clin. Genet. 2004, 65:202-208.
34. Ge L., Qi W., Wang L.-J., Miao H.-H., Qu Y.-X., Li B.-L., Song B.-L. Flotillins play an essential role in Niemann-Pick C1-like 1-mediated cholesterol uptake. Proc. Natl. Acad. Sci. 2011, 108:551-556.
35. Stitziel N.O., Won H.-H., Morrison A.C., Peloso G.M., Do R., Lange L.A., Fontanillas P., Gupta N., Duga S., Goel A. Inactivating mutations in NPC1L1 and protection from coronary heart disease. N. Engl. J. Med. 2014, 371:2072.
36. Cannon C. IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) 2014, American Heart Association Scientific Sessions, Chicago.
37. Inactivating mutations in NPC1L1 and protection from coronary heart disease. N. Engl. J. Med. 2014, 371:2072-2082.
38. Mutations in NPC1L1 and coronary heart disease. N. Engl. J. Med. 2015, 372:881-883.
39. Muendlein A., Leiherer A., Saely C.H., Rein P., Zanolin D., Kinz E., Brandtner E.-M., Fraunberger P., Drexel H. Common single nucleotide polymorphisms at the NPC1L1 gene locus significantly predict cardiovascular risk in coronary patients. Atherosclerosis 2015, 242:340-345.
40. Wang J., Williams C.M., Hegele R.A. Compound heterozygosity for two non-synonymous polymorphisms in NPC1L1 in a non-responder to ezetimibe. Clin. Genet. 2005, 67:175-177.
41. Zhang J.-H., Ge L., Qi W., Zhang L., Miao H.-H., Li B.-L., Yang M., Song B.-L. The N-terminal domain of NPC1L1 protein binds cholesterol and plays essential roles in cholesterol uptake. J. Biol. Chem. 2011, 286:25088-25097.
42. Ge L., Wang J., Qi W., Miao H.-H., Cao J., Qu Y.-X., Li B.-L., Song B.-L. The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced internalization of NPC1L1. Cell Metab. 2008, 7:508-519.
43. Cremona M.L., Matthies H.J.G., Pau K., Bowton E., Speed N., Lute B.J., Anderson M., Sen N., Robertson S.D., Vaughan R.A., Rothman J.E., Galli A., Javitch J.A., Yamamoto A. Flotillin-1 is essential for PKC-triggered endocytosis and membrane microdomain localization of DAT. Nat. Neurosci. 2011, 14:469-477.
44. Bauer M., Pelkmans L. A new paradigm for membrane-organizing and -shaping scaffolds. FEBS Lett. 2006, 580:5559-5564.
45. Otto G.P., Nichols B.J. The roles of flotillin microdomains - endocytosis and beyond. J. Cell Sci. 2011, 124:3933-3940.
46. Cohen J.C., Boerwinkle E., Mosley T.H., Hobbs H.H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 2006, 354:1264-1272.
47. Blom D.J., Hala T., Bolognese M., Lillestol M.J., Toth P.D., Burgess L., Ceska R., Roth E., Koren M.J., Ballantyne C.M. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N. Engl. J. Med. 2014, 370:1809-1819.